Abstract: Objective    To explore the therapeutic effect of  anti-complement 5a receptor (anti-C5aR) antibody combined with allicin on inflammatory bowel disease (IBD) in rats. Methods     Eighty IBD male rats induced by 2,4,6-trinitrobenzenesulfonic acid sol (TNBS) were randomly divided into 4 groups: model control group, anti-C5aR antibody treatment group, allicin treatment group and  anti-C5aR antibody combined with allicin treatment group, another 20 normal male rats were used as the normal control group. The changes in body weight and survival rate, serum interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) levels, colonic tissue gross observation and pathological score were measured before and 14 d after drug intragastric administration. Results   The body weight and  survival rate of the rats treated with anti-C5aR antibody combined with allicin were higher than those of other treatment groups, and the expression of inflammatory cytokines IL-6 and TNF-α in the serum of the rats treated with the combination of anti-C5aR antibody and allicin showed a significant regression trend with the time. The histopathological score of the colon also suggested that anti-C5aR antibody combined with allicin had the best effect (P<0.05) in the treatment of IBD. Conclusion     Anti-C5aR antibody combined with allicin is an effective treatment for TNBS-induced colitis, and its efficacy is better than anti-C5aR antibody or allicin alone.

Key words: Anti-C5aR antibody, Allicin, Inflammatory bowel disease, 2,4,6-trinitrobenzenesulfonic acid sol, Rats